Support us
<p>Senescent cancer cells</p>

Rene Bernards

Functional cancer genetics

My group uses genome-wide functional genetic approaches to identify powerful drug combinations, new drug targets and mechanisms of resistance to cancer drugs. We focus on induction of senescence as a new therapeutic modality for cancer therapy.

In addition, we study how combinations of drugs that act in the MAP kinase pathway can help improve responses in patients with perturbations of this pathway. We aim to bring our discoveries to the clinic in close collaboration with the clinicians of our affiliated hospital.


Highlight of this group

Fig.1 Bernards

Regulatory approval  for the combination of BRAF and EGFR inhibition in BRAF mutant colon cancer

Is based on our 2012 discovery of the effectiveness of this drug combination (PMID: 22281684 and link to FDA

Contact our group

NKI Placeholder Profiel
Patty Lagerweij Office Manager

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.